机构：[1]Laboratory of Tumor Biology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, China[2]Department of Medical Oncology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, China[3]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, China
Solamargine (SM) has been shown to have anti-cancer properties. However, the underlying mechanism involved remains undetermined. We showed that SM inhibited the growth of non-small cell lung cancer (NSCLC) cells, which was enhanced in cells with silencing of long non-coding RNA (lncRNA) HOX transcript antisense RNA (HOTAIR), while it overcame by overexpression of HOTAIR. In addition, SM increased the expression of miR-214-3p and inhibited 3-phosphoinositide-dependent protein kinase-1 (PDPK1) gene expression, which was strengthened by miR-214-3p mimics. Intriguingly, HOTAIR could directly bind to miR-214-3p and sequestered miR-214-3p from the target gene PDPK1. Intriguingly, overexpression of PDPK1 overcame the effects of SM on miR-214-3p expressions and neutralized the SM-inhibited cell growth. Similar results were observed in vivo. In summary, our results showed that SM-inhibited NSCLC cell growth through the reciprocal interaction between HOTAIR and miR-214-3p, which ultimately suppressed PDPK1 gene expression. HOTAIR effectively acted as a competing endogenous RNA (ceRNA) to stimulate the expression of target gene PDPK1. These complex interactions and feedback mechanisms contribute to the overall effect of SM. This unveils a novel molecular mechanism underlying the anti-cancer effect of SM in human lung cancer.
基金：
The Major Program of National Natural
Science Foundation of Guangdong, Grant/
Award Number: 2018B030311061;
The Science and Technology Program
of Guangzhou, Grant/Award Number:
201607010385; The Specific Research
Fund for TCM Science and Technology
of Guangdong Provincial Hospital of
Chinese Medicine, Grant/Award Number:
YN2015MS19; Science and Technology
Planning Project of Guangdong Province,
Grant/Award Number: 2017B030314166;
National Nature Scientific Foundation of
China, Grant/Award Number: 81403216,
81703551 and 81871863; The Special
Science and Technology Join fund from
Guangdong Provincial Department of
Science and Technology‐Guangdong
Academy of Traditional Chinese Medicine,
Grant/Award Number: 2014A020221024;
The Discipline of Integrated Chinese and
Western Medicine in Guangzhou University
of Chinese Medicine, Grant/Award Number:
A1‐Af‐D018161Z1513
第一作者机构：[1]Laboratory of Tumor Biology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, China
通讯作者：
通讯机构：[1]Laboratory of Tumor Biology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, China[2]Department of Medical Oncology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, China[3]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, China[*1]No. 111, Dade Road, Guangzhou, Guangdong Province 510120, China.
推荐引用方式(GB/T 7714)：
Tang Qing,Zheng Fang,Liu Zheng,et al.Novel reciprocal interaction of lncRNA HOTAIR and miR-214-3p contribute to the solamargine-inhibited PDPK1 gene expression in human lung cancer[J].JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2019,23(11):7749-7761.doi:10.1111/jcmm.14649.
APA：
Tang, Qing,Zheng, Fang,Liu, Zheng,Wu, JingJing,Chai, XiaoSu...&Hann, Swei Sunny.(2019).Novel reciprocal interaction of lncRNA HOTAIR and miR-214-3p contribute to the solamargine-inhibited PDPK1 gene expression in human lung cancer.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,23,(11)
MLA：
Tang, Qing,et al."Novel reciprocal interaction of lncRNA HOTAIR and miR-214-3p contribute to the solamargine-inhibited PDPK1 gene expression in human lung cancer".JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 23..11(2019):7749-7761
